Orchid Pharma Ltd.
Snapshot View

311.00 +9.75 ▲3.2%

20 May 2022, 04:01:00 PM
Volume: 1,970

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.orchidpharma.com
Market Cap 1,269.39 Cr.
Enterprise Value(EV) 1,529.28 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) -0.48 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-03
Industry PE 29.26 Trailing Twelve Months Ending 2022-03
Book Value / Share 145.16 Trailing Twelve Months Ending 2022-03
Price to Book Value 2.14 Calculated using Price: 311.00
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 4.08 Cr. 40,816,400 Shares
FaceValue 10
Company Profile

Orchid Chemicals & Pharmaceuticals (Orchid) is pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was Incorporated in the year 1992 as a 100% export-oriented unit (EOU).

Orchid has employee strength of over 3700 people, out of which over 600 are scientists, technologists and other professionals.

The drug major has two manufacturing unit for APIs located at Alathur and Aurangabad and three facilities for fosage forms at Irungattukottai and Alathur. Besides this it two research and development centres located at Sholinganallur and Irungattukottai, Chennai.

It has formed an alliance with North China Pharmaceutical Corporation (NCPC), which is the largest pharmaceutical group in China to manufacture and market pharmaceuticals products.

The company has formed distribution and marketing alliance with various global pharmaceutical corporations including Apotex, Actavis, Hospira and Dava, among others.

Orchid owns two subsidiaries, whose core focus are on drug discovery and development namely Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. Besides this, it also has subsidiary such as Orgenus Pharma Inc (USA), Orchid Pharmaceuticals Inc (USA), Ogna Farma (South America) and Orchid Europe.

During March 2010, Orchid Chemicals & Pharmaceuticals had completed the transaction for sale and transfer of Orchid's generic injectable finished dosage forms Pharmaceuticals business to Hospira Healthcare India, a subsidiary of Hospira, Inc.

In January 2011, Orchid Chemicals & Pharmaceuticals had signed a memorandum of understanding with Great Lakes Institute of Management for setting up a centre of excellence in technopreneurship at Great Lakes campus near Chennai. The MoU was signed in the presence of APJ Abdul Kalam, former President of India, during the inauguration of Great Lakes' B-school festival, L’Attitude 13° 05’.

In April 2011, Orchid Chemicals had attained an out-of-court settlement with world's largest drug maker Pfizer Inc to sell a low-cost version of the American firm's patented anti-depressant drug, Effexor XR, (extended release) in the US market this fiscal.

In 2012
 - Orchid Pharma exit its Chinese JV with NCPC
 - Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million

In 2013
- Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics

Products

Active Pharmaceutical Ingredients- Orchid develops a wide range of APIs in category of oral cephalosporins, betalactams, special nutraceuticals, etc.

Formulations- Under this the company is engaged in developing formulation in various segment such anti-infectives, anti-oxidants, oral anti-diabetics, etc.

Awards


Orchid was awarded as the Top Indian Public Limited Company in Patent at the 5th National Intellectual Property Award 2013, organized by CII in partnership with the Department of Industrial Policy & Promotion and Indian Intellectual Property Office, Government of India.
Orchid received EXIM Achievement Award 2012 for its meritorious export performance by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ – Special Economic Zone, Government of India.

Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Hon’ble Chief Minister of Andhra Pradesh.
Orchid was awarded IGCW – 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.

Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.

In 2010, for ""Outstanding Achievement in Environment Management in the Chemical sector"", Orchid was conferred with the Silver Award by Greentech Foundation.

Orchid was awarded the ""Siemens Ecovatives-IBN Live Award 2010"" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).

In 2010, Orchid’s Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.

Orchid’s endeavour in the area of energy conservation was recognised with the “Excellent Energy Efficient Unit” in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.

Orchid’s Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune)

Orchid's Alathur facility was awarded Certificate of Appreciation by the National Safety Council of India (Safety Awards - 2011) in recognition of its appreciable achievement in Occupational Safety & Health during the assessment period of three years from 2008-10.

In 2011, Orchid received the ""Green Tech Gold Safety Award"" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India  and Mr Kamaleshwar Sharan, President, Greentech Foundation.

Orchid’s Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.

Orchid was awarded the ""Certificate of Merit Award"" for 2010 by the CII for Excellence in Environment, Health and Safety.

Orchid Research Laboratories (the discovery subsidiary of Orchid) won the Partner of Choice Award for Contract Research - Collaborative Drug Discovery by Frost & Sullivan in April 2007.

The company also bagged Gold Award for Excellence and Business Prestige was awarded at the Quality Summit 2003, New York.

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.24%
1 Week
-1.03%
1 Month
-17.62%
3 Month
+6.56%
6 Month
-22.98%
1 Year
-79.04%
2 Year
+5823.81%
5 Year
+862.85%
10 Year
+144.02%
9 years 2012-03 2013-09 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 8.86 -74.06 -55.58 -147.51 -423.17 -16.43
Return on Capital Employed (%) 8.12 -1.48 4.17 -0.06 -6.93 -3.46 3.08 -6.47 -5.28
Return on Assets (%) 2.48 -13.04 -4.53 -7.05 -13.59 -10.88 2.24 -5.78 -8.64

Balance Sheet View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 1,132 380 329 49 -388 -792 -704 766 653 647
Non Curr. Liab. 1,252 1,064 2,609 2,475 2,205 1,905 1,436 519 442 222
Curr. Liab. 1,551 3,206 1,123 1,338 1,541 2,013 2,346 175 142 241
Minority Int. 3 1
Equity & Liab. 3,938 4,651 4,061 3,862 3,358 3,125 3,077 1,460 1,237 1,111
Non Curr. Assets 2,685 3,550 2,783 2,611 2,479 2,446 2,310 891 687 661
Curr. Assets 1,253 1,101 1,278 1,251 879 679 767 569 550 450
Misc. Exp. not W/O
Total Assets 3,938 4,651 4,061 3,862 3,358 3,125 3,077 1,460 1,237 1,111

Profit Loss View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 1,874 1,948 1,747 873 797 683 600 484 450 560
Other Income 56 41 42 25 19 20 17 24 15 9
Total Income 1,930 1,988 1,789 898 816 703 617 508 465 569
Total Expenditure -1,517 -1,837 -1,429 -703 -709 -659 -612 -515 -421 -510
PBIDT 413 151 360 196 106 45 5 -7 45 59
Interest -180 -523 -537 -294 -331 -310 -7 -6 -52 -32
Depreciation -154 -252 -325 -145 -141 -133 -130 -118 -109 -87
Taxation 22 13 191 17 48 46
Exceptional Items -4 51 113 -53 -173 201
PAT 97 -560 -197 -279 -490 -353 69 -131 -117 -60
Minority Interest 2 1
Share Associate 0
Other Related Items
Consolidated Net Profit 97 -558 -197 -279 -490 -353 70 -131 -117 -2
Adjusted EPS 14 -79 -23 -31 -55 -40 8 -32 -29 0

Cash Flow View Details

Particulars 10 years 2011-03 Rs. Cr. 2012-03 Rs. Cr. 2013-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 332 737 168 -369 212 317 9 12 81 24
Cash Fr. Inv. -367 -293 -986 1,334 -1 -9 -28 45 167 67
Cash Fr. Finan. -78 -480 664 -597 -286 -366 33 0 -250 -165
Net Change -113 -36 -153 367 -76 -58 15 57 -2 -74
Cash & Cash Eqvt 213 177 23 391 315 257 35 92 90 16

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 26.68 26.68 26.68 98.07 98.07 90.00 90.00 90.00 90.00
Public 73.32 73.32 73.32 1.93 1.93 10.00 10.00 10.00 10.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 99.96 99.96 99.95 0.04 0.04 32.68 32.68 32.68 0.00

Announcements View Details

Tue, 17 May 2022
Board Meeting Outcome for Revised Outcome
Revised outcome - Audited financial results-March 31 2022-Legible format
Mon, 16 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publications-Audited financial results for the quarter and year ended March 31 2022
Sun, 15 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company Orchid Pharma Ltd
2 CIN NO. L24222TN1992PLC022994
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2020-2021 2021-2022
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2020-2021 2021-2022
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-Nikita
Designation :-Company Secretary
Name of the Chief Financial Officer :- Sunil Gupta
Designation : -Chief financial officer

Date: 15/05/2022

Technical Scans View Details

Fri, 20 May 2022
Closing Above Previous High Closing Above Previous High
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year
High Increase 2 Years High Increase 2 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%